SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Clinical trial NCT05375084 · TERMINATED

Trial details

NCT number: NCT05375084
Sponsor: Navire Pharma Inc., a BridgeBio company
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Solid Tumor

Start date: 2022-10-20
Primary completion: 2024-04-12
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.